Ellie G😷
@izzybear.bsky.social
Mental health professional, COVID conscience mask wearer, social justice advocate, supporter of science, public education & universal healthcare. She/her🌈
Reposted by Ellie G😷
Sparsentan for FSGS?? It's alive....
ir.travere.com/press-releas...
ir.travere.com/press-releas...
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
PDUFA target action date of January 13, 2026 If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Travere Th...
ir.travere.com
May 20, 2025 at 5:53 PM
Sparsentan for FSGS?? It's alive....
ir.travere.com/press-releas...
ir.travere.com/press-releas...
Reposted by Ellie G😷
T3b: Obinutuzumab achieved sustained B-cell depletion (CD19+ <10/µL) in 95% of patients through week 76, outperforming Rituximab (~80% at week 52, LUNAR trial).
pubmed.ncbi.nlm.nih....
Obvious question: why REGENCY was positive and LUNAR negative? #nephJC
pubmed.ncbi.nlm.nih....
Obvious question: why REGENCY was positive and LUNAR negative? #nephJC
March 12, 2025 at 1:47 AM
T3b: Obinutuzumab achieved sustained B-cell depletion (CD19+ <10/µL) in 95% of patients through week 76, outperforming Rituximab (~80% at week 52, LUNAR trial).
pubmed.ncbi.nlm.nih....
Obvious question: why REGENCY was positive and LUNAR negative? #nephJC
pubmed.ncbi.nlm.nih....
Obvious question: why REGENCY was positive and LUNAR negative? #nephJC
Reposted by Ellie G😷
T2e: With obinutuzumab there was a greater reduction in protein-to-creatinine ratio (adjusted difference 13.7%) #NephJC
Proteinuric response (UPCR <0.8 g per gram) without intercurrent events was significantly higher in the obinutuzumab arm (55.5% vs 41.9%)
Proteinuric response (UPCR <0.8 g per gram) without intercurrent events was significantly higher in the obinutuzumab arm (55.5% vs 41.9%)
March 12, 2025 at 1:33 AM
T2e: With obinutuzumab there was a greater reduction in protein-to-creatinine ratio (adjusted difference 13.7%) #NephJC
Proteinuric response (UPCR <0.8 g per gram) without intercurrent events was significantly higher in the obinutuzumab arm (55.5% vs 41.9%)
Proteinuric response (UPCR <0.8 g per gram) without intercurrent events was significantly higher in the obinutuzumab arm (55.5% vs 41.9%)
Reposted by Ellie G😷
Tonite at 9pm, only on #Blusky, we discuss the new kid on the block for lupus nephritis! Join us for nephrology education as we close in on #WorldKidneyDay #NephSky
Obinutuzumab, a super B-Cell destroyer 💥
www.nephjc.com/news/regency...
Obinutuzumab, a super B-Cell destroyer 💥
www.nephjc.com/news/regency...
Obinutuzumab in Lupus Nephritis — NephJC
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not ...
www.nephjc.com
March 11, 2025 at 11:45 AM
Tonite at 9pm, only on #Blusky, we discuss the new kid on the block for lupus nephritis! Join us for nephrology education as we close in on #WorldKidneyDay #NephSky
Obinutuzumab, a super B-Cell destroyer 💥
www.nephjc.com/news/regency...
Obinutuzumab, a super B-Cell destroyer 💥
www.nephjc.com/news/regency...
Reposted by Ellie G😷
Rituximab-induced serum sickness (RISS) is a rare drug complication in patients w/steroid-dependent nephrotic syndrome (SDNS). Read these Clinical Insights on low-dose obinutuzumab for SDNS complicated by recurrent RISS & anti-rituximab antibodies.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
March 3, 2025 at 10:30 PM
Rituximab-induced serum sickness (RISS) is a rare drug complication in patients w/steroid-dependent nephrotic syndrome (SDNS). Read these Clinical Insights on low-dose obinutuzumab for SDNS complicated by recurrent RISS & anti-rituximab antibodies.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Reposted by Ellie G😷
Reposted by Ellie G😷
A new horizon in #FSGS coming soon?
Earlier this week, Travere Therapeutics announced plans to submit an sNDA for sparsentan (Filspari) based on DUPLEX trial and PARASOL data.
#Nephrology #FDANews
www.hcplive.com/view...
Earlier this week, Travere Therapeutics announced plans to submit an sNDA for sparsentan (Filspari) based on DUPLEX trial and PARASOL data.
#Nephrology #FDANews
www.hcplive.com/view...
February 16, 2025 at 3:18 AM
A new horizon in #FSGS coming soon?
Earlier this week, Travere Therapeutics announced plans to submit an sNDA for sparsentan (Filspari) based on DUPLEX trial and PARASOL data.
#Nephrology #FDANews
www.hcplive.com/view...
Earlier this week, Travere Therapeutics announced plans to submit an sNDA for sparsentan (Filspari) based on DUPLEX trial and PARASOL data.
#Nephrology #FDANews
www.hcplive.com/view...
Reposted by Ellie G😷
A study sought to shed light on whether GLP-1 receptor agonists reduce the risk of significant kidney outcomes and whether they have #kidney and #cardiovascular benefits for patients without #diabetes. #nephrology #nephsky #glp1ra
Effects of GLP-1 Receptor Agonists on Kidney and Cardiovascular Outcomes | Docwire News
A study examined whether GLP-1 receptor agonists improved clinically important kidney outcomes and whether patients without diabetes could benefit from treatment with them.
buff.ly
February 7, 2025 at 6:49 PM
A study sought to shed light on whether GLP-1 receptor agonists reduce the risk of significant kidney outcomes and whether they have #kidney and #cardiovascular benefits for patients without #diabetes. #nephrology #nephsky #glp1ra
Reposted by Ellie G😷
FLOW study in @nejm.org. MOA for renal protection with SEM likely multi factorial but independent of weight/glycemic control. #GLP1 RA’s reduce glomerular inflammation (⬇️ IL6), reduce fibrosis (⬇️ TGFb), & reduce vascular oxidative stress (⬆️NO, ⬇️ RAS). #RheumSky #NephSky #CardioMetabolic
January 30, 2025 at 1:00 AM
FLOW study in @nejm.org. MOA for renal protection with SEM likely multi factorial but independent of weight/glycemic control. #GLP1 RA’s reduce glomerular inflammation (⬇️ IL6), reduce fibrosis (⬇️ TGFb), & reduce vascular oxidative stress (⬆️NO, ⬇️ RAS). #RheumSky #NephSky #CardioMetabolic
Reposted by Ellie G😷
BREAKING NEWS: The FDA has approved Ozempic for patients with chronic kidney disease. This means the popular injection can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
www.cnbc.com
January 28, 2025 at 8:21 PM
BREAKING NEWS: The FDA has approved Ozempic for patients with chronic kidney disease. This means the popular injection can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.
Reposted by Ellie G😷
Ozempic now FDA approved for CKD!
January 28, 2025 at 10:49 PM
Ozempic now FDA approved for CKD!
Reposted by Ellie G😷
A study examined the efficacy and safety of obinutuzumab to treat patients with focal segmental glomerulosclerosis who were treatment-resistant or dependent on immunosuppressive therapy. #nephrology #nephsky #KidneyWk #FSGS #kidneydisease
Obinutuzumab Efficacy, Safety for FSGS Treatment | Docwire News
Obinutuzumab reduced proteinuria in patients with focal segmental glomerulosclerosis (FSGS) who were treatment-resistant or dependent on immunosuppressive therapy.
buff.ly
January 17, 2025 at 8:46 PM
A study examined the efficacy and safety of obinutuzumab to treat patients with focal segmental glomerulosclerosis who were treatment-resistant or dependent on immunosuppressive therapy. #nephrology #nephsky #KidneyWk #FSGS #kidneydisease
Reposted by Ellie G😷
🚀Mobilising advances in rare kidney disease🚀
The National Registry of Rare Kidney Diseases is a powerful data source helping to improve our understanding of rare kidney conditions & supporting clinical trials.
🔬Find out more about Radar: ukkidney.org/rare-renal/h...
The National Registry of Rare Kidney Diseases is a powerful data source helping to improve our understanding of rare kidney conditions & supporting clinical trials.
🔬Find out more about Radar: ukkidney.org/rare-renal/h...
January 10, 2025 at 4:15 PM
🚀Mobilising advances in rare kidney disease🚀
The National Registry of Rare Kidney Diseases is a powerful data source helping to improve our understanding of rare kidney conditions & supporting clinical trials.
🔬Find out more about Radar: ukkidney.org/rare-renal/h...
The National Registry of Rare Kidney Diseases is a powerful data source helping to improve our understanding of rare kidney conditions & supporting clinical trials.
🔬Find out more about Radar: ukkidney.org/rare-renal/h...
Reposted by Ellie G😷
📣 Have you heard? The American College of Rheumatology has issued a summary of a new guideline for lupus nephritis. #rheumatology #nephrology #nephsky #lupusnephritis
ACR Issues Summary of New Lupus Nephritis Guidance | Docwire News
The American College of Rheumatology issued a summary of a new guideline for the screening, treatment, and management of lupus nephritis that will be published in 2025.
buff.ly
January 3, 2025 at 2:06 PM
📣 Have you heard? The American College of Rheumatology has issued a summary of a new guideline for lupus nephritis. #rheumatology #nephrology #nephsky #lupusnephritis
Reposted by Ellie G😷
Optimal rituximab dosing when given w/mycophenolate mofetil (MMF) for frequently relapsing nephrotic syndrome/steroid-dependent nephrotic syndrome remains uncertain. Read this Original Article comparing single vs. double dose of rituximab w/MMF.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
January 3, 2025 at 7:04 PM
Optimal rituximab dosing when given w/mycophenolate mofetil (MMF) for frequently relapsing nephrotic syndrome/steroid-dependent nephrotic syndrome remains uncertain. Read this Original Article comparing single vs. double dose of rituximab w/MMF.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Reposted by Ellie G😷
The study used bidirectional Mendelian randomization to examine causality between inflammatory skin diseases and #IgAN. #nephrology #skindisease #iganephropathy #nephsky
Association Between Inflammatory Skin Diseases and IgA Nephropathy | Docwire News
A study examined a possible link between IgA nephropathy (IgAN) and inflammatory skin diseases, such as atopic dermatitis, acne, and psoriasis.
buff.ly
December 14, 2024 at 4:05 PM
The study used bidirectional Mendelian randomization to examine causality between inflammatory skin diseases and #IgAN. #nephrology #skindisease #iganephropathy #nephsky
Reposted by Ellie G😷
We've kicked off the first-ever #rFSGSConference! We look forward to an impactful day by and for #rFSGS patients. #RareDisease #KidneyTransplant
December 9, 2024 at 2:20 PM
We've kicked off the first-ever #rFSGSConference! We look forward to an impactful day by and for #rFSGS patients. #RareDisease #KidneyTransplant
Reposted by Ellie G😷
Combination induction immunosuppression with rituximab, cyclophosphamide, and prednisone for fibrillary glomerulonephritis
#nephsky
www.kireports.org/article/S246...
#nephsky
www.kireports.org/article/S246...
DEFINE_ME
www.kireports.org
November 30, 2024 at 8:45 AM
Combination induction immunosuppression with rituximab, cyclophosphamide, and prednisone for fibrillary glomerulonephritis
#nephsky
www.kireports.org/article/S246...
#nephsky
www.kireports.org/article/S246...
I wish I could say I was surprised 😢
This should be front page news. 70% of patients requiring the hospital for Covid CAUGHT it in healthcare.
That’s an alarming amount of completely preventable hospitalizations.
Healthcare settings know how to stop spread.
Clean air & mandatory respirators. Forcibly infecting patients is wrong 🧵/1
That’s an alarming amount of completely preventable hospitalizations.
Healthcare settings know how to stop spread.
Clean air & mandatory respirators. Forcibly infecting patients is wrong 🧵/1
November 28, 2024 at 5:24 PM
I wish I could say I was surprised 😢
My thoughts exactly.
Dear rest of Canada,
Please, please, help those of us stuck in Alberta.
We're not all right-wing nuts. Some of us care deeply about the environment, LGBTQ rights, children's mental health, women's rights, & the other provinces' well-being. We want to keep the CPP.
Signed,
Can't move from AB
Please, please, help those of us stuck in Alberta.
We're not all right-wing nuts. Some of us care deeply about the environment, LGBTQ rights, children's mental health, women's rights, & the other provinces' well-being. We want to keep the CPP.
Signed,
Can't move from AB
November 28, 2024 at 1:41 AM
My thoughts exactly.
Reposted by Ellie G😷
I’m thrilled that our project investigating public understandings of immunity systems and human-microbial relations has been funded by the Australian Research Council
November 26, 2024 at 4:10 AM
I’m thrilled that our project investigating public understandings of immunity systems and human-microbial relations has been funded by the Australian Research Council
Reposted by Ellie G😷
🆕 Antibody identified in podocytopathies 🫘after Anti nephrin Ab⭐
Anti Slit diaphragm Ab ‼️‼️‼️
The heterogeneity in response to immunosuppression is understandable now!
#Nephsky
Anti Slit diaphragm Ab ‼️‼️‼️
The heterogeneity in response to immunosuppression is understandable now!
#Nephsky
November 24, 2024 at 8:43 AM
🆕 Antibody identified in podocytopathies 🫘after Anti nephrin Ab⭐
Anti Slit diaphragm Ab ‼️‼️‼️
The heterogeneity in response to immunosuppression is understandable now!
#Nephsky
Anti Slit diaphragm Ab ‼️‼️‼️
The heterogeneity in response to immunosuppression is understandable now!
#Nephsky
Reposted by Ellie G😷
“Long COVID is not a psychological condition. It is a medical condition, and it should be treated as such”
Psychologizing people with Long Covid is dangerous. It prevents them from getting the care they need.
Once they understand it’s a severe medical condition - they MAY mask up avoid reinfection
Psychologizing people with Long Covid is dangerous. It prevents them from getting the care they need.
Once they understand it’s a severe medical condition - they MAY mask up avoid reinfection
A new definition of Long COVID
New research and a formal definition of Long COVID from the National Academies of Sciences, Engineering, and Medicine can guide psychologists in helping patients battling the condition
www.apa.org
November 24, 2024 at 8:56 PM
“Long COVID is not a psychological condition. It is a medical condition, and it should be treated as such”
Psychologizing people with Long Covid is dangerous. It prevents them from getting the care they need.
Once they understand it’s a severe medical condition - they MAY mask up avoid reinfection
Psychologizing people with Long Covid is dangerous. It prevents them from getting the care they need.
Once they understand it’s a severe medical condition - they MAY mask up avoid reinfection